SCHEMBL4462189

SCHEMBL4462189

c1ccc(-c2nc(-c3cccs3)oc2-c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 3/20 0.53
▸ ALDH1A1 P00352 8/20 0.50
▸ HPGD P15428 7/20 0.50
▸ SMN1; SMN2 Q16637 5/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ MAPK13 O15264 1/20 0.50
▸ MAPK12 P53778 1/20 0.50
▸ MAPK11 Q15759 1/20 0.50
▸ MAPK14 Q16539 1/20 0.50
▸ F2 P00734 1/20 0.50
▸ KDM4E B2RXH2 8/20 0.49
▸ RAB9A P51151 6/20 0.49
▸ NPC1 O15118 5/20 0.49
▸ GPR55 Q9Y2T6 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ MAPT P10636 4/20 0.48
▸ CYP1A2 P05177 3/20 0.48
▸ CYP2C19 P33261 3/20 0.48
▸ CYP2C9 P11712 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29580874 0.82 MEN1 (0.48) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL29421049 0.81 PDE4C (0.49) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL762311 0.79 NR4A2 (0.62) NR4A2ALDH1A1HPGDSMN1; SMN2MAPK13
SCHEMBL29154651 0.76 MAPK13 (0.60) NR4A2ALDH1A1HPGDSMN1; SMN2MEN1
SCHEMBL7808125 0.74 USP1 (0.61) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL22761529 0.73 NR4A2 (0.55) NR4A2ALDH1A1HPGDSMN1; SMN2MEN1
SCHEMBL7059841 0.73 ALDH1A1 (0.73) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
Dimethylamine SCHEMBL8172161 0.73 MAPK13 (0.56) NR4A2ALDH1A1HPGDSMN1; SMN2MAPK13
SCHEMBL23949970 0.72 ALDH1A1 (0.55) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL6958523 0.70 NPC1 (0.66) NR4A2ALDH1A1HPGDSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1121129-B1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS BRISTOL MYERS SQUIBB CO (US) 2008-09-03 — — EP claimed
US-7390824-B1 Method for treating diabetes employing an aP2 inhibitor and combination BRISTOL-MYERS SQUIBB COMPANY (US) 2008-06-24 — — US claimed
US-20040229807-A1 Method for treating atherosclerosis employing an aP2 inhibitor and combination PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2004-11-18 — — US claimed
EP-1121129-A4 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL MYERS SQUIBB CO (US) 2002-10-16 — — EP claimed
EP-1113801-A4 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL MYERS SQUIBB CO (US) 2002-10-02 — — EP claimed
JP-2002524518-A — — 2002-08-06 — — JP claimed
JP-2002524517-A — — 2002-08-06 — — JP claimed
US-20020035064-A1 Method for treating atherosclerosis employing an aP2 inhibitor and combination BRISTOL-MYERS SQUIBB COMPANY 2002-03-21 — — US claimed
EP-1121129-A1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-08 — — EP claimed
EP-1113801-A1 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL-MYERS SQUIBB COMPANY (US) 2001-07-11 — — EP claimed
WO-2000015230-A1 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL-MYERS SQUIBB COMPANY (US) 2000-03-23 — — WO claimed
WO-2000015229-A1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL-MYERS SQUIBB COMPANY (US) 2000-03-23 — — WO claimed
US-20090076033-A1 Method for treating atherosclerosis employing an aP2 inhibitor and combination ROBL JEFFREY A 2009-03-19 — — US disclosed
EP-1121129-B1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS BRISTOL MYERS SQUIBB CO (US) 2008-09-03 — — EP disclosed
US-7390824-B1 Method for treating diabetes employing an aP2 inhibitor and combination BRISTOL-MYERS SQUIBB COMPANY (US) 2008-06-24 — — US disclosed
US-7358254-B2 Method for treating atherosclerosis employing an aP2 inhibitor and combination BRISTOL-MYERS SQUIBB COMPANY (US) 2008-04-15 — — US disclosed
EP-1121129-A1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-08 — — EP disclosed
EP-1113801-A1 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL-MYERS SQUIBB COMPANY (US) 2001-07-11 — — EP disclosed
WO-2000015230-A1 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL-MYERS SQUIBB COMPANY (US) 2000-03-23 — — WO disclosed
WO-2000015229-A1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL-MYERS SQUIBB COMPANY (US) 2000-03-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035064-A1 Method for treating atherosclerosis employing an aP2 inhibitor and combination SREBF2, SREBF1, AP2A2 NR4A2 357/4885ALDH1A1 4196/4885HPGD 1519/4885
US-20040229807-A1 Method for treating atherosclerosis employing an aP2 inhibitor and combination SREBF2, SREBF1, AP2A2 NR4A2 357/4885ALDH1A1 4196/4885HPGD 1519/4885
US-20090076033-A1 Method for treating atherosclerosis employing an aP2 inhibitor and combination SREBF2, SREBF1, HMGCR NR4A2 705/4885ALDH1A1 4193/4885HPGD 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback